Competitor Analysis: Selective Estrogen Receptor Modulators

Product Code LME00101
Publication Date January 2010
Publisher La Merie
Product Type Report
Pages 19
ISBN Number not applicable
Change currency
PDF £125.00 €151 $198 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Competitor Analysis: Selective Estrogen Receptor Modulators

Product description

The present Competitive Intelligence Report about Selective Estrogen Receptor Modulators (SERM) provides a competitor evaluation in the field of small molecules selectively modulating estrogen receptor (SERM) as of January 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ER) agonists or antagonist depending on the targeted tissue and the specific configuration of the used SERM. Effects on bone, endometrium and breast cancer are of interest. Tamoxifen is the widely investigated and most used representative of these drugs and has been introduced in treatment advanced breast cancer, in the neoadjuvant and adjuvant setting and for prevention of the disease. Other compounds are in development for breast cancer. The ongoing need for new osteoporosis therapies has led to the development of new selective estrogen receptor modulators (SERMs) with an ideal tissue selectivity profile and beneficial effects on bone without undesirable effects on the endometrium and breast.

The report includes a compilation of currently active projects in research and development of small molecules selectively modulating estrogen receptor (SERM). In addition, the report lists company-specific R&D pipelines of selective estrogen receptor modulators. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Contents

  • Index
    • Selective Estrogen Receptor Modulators
    • Corporate SERM R&D Pipelines
    • About La Merie